Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

esketamine

- PMLiVE

J&J brings its Care4today mobile adherence programme to the UK

Launches the mobile app in its first market outside the US

- PMLiVE

J&J’s Care4Today brand joins Twitter

Firm's Janssen Healthcare Innovation unit also makes its debut on the social network

- PMLiVE

Shire’s ADHD drug fails in depression trial

Company drops Vyvanse for use in major depressive disorder

- PMLiVE

J&J sells diagnostics unit to private equity firm

Ortho-Clinical Diagnostics acquired by the Carlyle Group

- PMLiVE

J&J’s combo diabetes drug held up by FDA

Regulator wants more dosing data on canaglifozin / metformin product

- PMLiVE

First Cymbalta generics approved in the US

Lilly prepares for onslaught of competition for antidepressant

- PMLiVE

Lilly depression drug fails late-stage trials

Will not pursue edivoxetine as an add-on treatment for depression

- PMLiVE

Pipeline: Major depressive disorder therapeutics

There are limited pipeline prospects to address this significant health issue

The Difficulties of Living with Depression Don’t End with the Illness Itself

This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.

Research Partnership

- PMLiVE

FDA clears J&J’s breakthrough lymphoma therapy

Imbruvica approved to treat mantle cell lymphoma

- PMLiVE

J&J pays $2bn to settle Risperdal mis-selling claims

Concludes nine-year investigation into marketing activities

- PMLiVE

EMA backs Lundbeck’s Brintellix in depression

Drug recommended for approval to treat major depressive episodes in adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links